173 related articles for article (PubMed ID: 31749992)
1. Innovative oncology products: time to revisit the strategy development?
Krendyukov A
ESMO Open; 2019; 4(5):e000571. PubMed ID: 31749992
[No Abstract] [Full Text] [Related]
2. Cost of cancer care: issues and implications.
Meropol NJ; Schulman KA
J Clin Oncol; 2007 Jan; 25(2):180-6. PubMed ID: 17210937
[TBL] [Abstract][Full Text] [Related]
3. Why oncologists need technology to succeed in alternative payment models.
Fargnoli B; Holleran R; Kolodziej M
Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP196-SP198. PubMed ID: 28665678
[No Abstract] [Full Text] [Related]
4. Venturing outside. Providers try outsourcing to bolster cancer-care programs as new technologies, reimbursement pressures add to challenges.
Zigmond J
Mod Healthc; 2007 Oct; 37(42):26-8. PubMed ID: 18020049
[No Abstract] [Full Text] [Related]
5. Oncology business development global summit.
Bockman JM; Nalam S
IDrugs; 2005 Jan; 8(1):37-40. PubMed ID: 15650940
[No Abstract] [Full Text] [Related]
6. The future of best investing in vaccines: the Health Technology Assessment approach.
La Torre G; de Waure C; Chiaradia G; Mannocci A; Specchia ML; Nicolotti N; Ricciardi W
Vaccine; 2008 Mar; 26(13):1609-10. PubMed ID: 18289744
[TBL] [Abstract][Full Text] [Related]
7. Losing sight of our primary target: curing cancer.
Marshall JL
Semin Oncol; 2014 Apr; 41(2):143-4. PubMed ID: 24787287
[No Abstract] [Full Text] [Related]
8. The promise of biomedical innovation.
Weil AR
Health Aff (Millwood); 2015 Feb; 34(2):198. PubMed ID: 25646097
[No Abstract] [Full Text] [Related]
9. Mobile economics and pricing of health care services.
Huttin CC
Technol Health Care; 2012; 20(5):459-61. PubMed ID: 23079949
[TBL] [Abstract][Full Text] [Related]
10. Impact of innovation in oncology: more questions than answers.
Fasola G; Barducci MC; Beretta G
Tumori; 2021 Dec; 107(6):478-482. PubMed ID: 34180297
[TBL] [Abstract][Full Text] [Related]
11. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
12. Life sciences venture capital in emerging markets.
Chakma J; Sammut SM; Agrawal A
Nat Biotechnol; 2013 Mar; 31(3):195-201. PubMed ID: 23471064
[No Abstract] [Full Text] [Related]
13. The high cost of cancer drugs and what we can do about it.
Siddiqui M; Rajkumar SV
Mayo Clin Proc; 2012 Oct; 87(10):935-43. PubMed ID: 23036669
[No Abstract] [Full Text] [Related]
14. Key factors impacting the delivery and financing of oncology care in the United States.
Goldsmith PJ; Paivanas T
J Natl Compr Canc Netw; 2006 May; 4(5):434-7. PubMed ID: 16715607
[No Abstract] [Full Text] [Related]
15. Trends in oncology drug innovation in China.
Li G; Qin Y; Xie C; Wu YL; Chen X
Nat Rev Drug Discov; 2021 Jan; 20(1):15-16. PubMed ID: 33154536
[No Abstract] [Full Text] [Related]
16. Oncology issues in health care reform.
Kennedy BJ
Cancer Invest; 1994; 12(2):249-56. PubMed ID: 8131102
[No Abstract] [Full Text] [Related]
17. Equity in cancer care: pathways, protocols, and guidelines.
DeMartino JK; Larsen JK
J Natl Compr Canc Netw; 2012 Oct; 10 Suppl 1():S1-9. PubMed ID: 23042831
[TBL] [Abstract][Full Text] [Related]
18. Medical Affairs and Innovative Medicinal Product Strategy Development.
Krendyukov A; Nasy D
Pharmaceut Med; 2022 Apr; 36(2):71-82. PubMed ID: 35279795
[TBL] [Abstract][Full Text] [Related]
19. Not at any cost: organizations help patients cope with costs of cancer care.
Printz C
Cancer; 2011 Mar; 117(5):879. PubMed ID: 21351079
[No Abstract] [Full Text] [Related]
20. The war on cancer: progress at what price?
Konski A
J Clin Oncol; 2011 Apr; 29(12):1503-4. PubMed ID: 21402613
[No Abstract] [Full Text] [Related]
[Next] [New Search]
